Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes

European Journal of Clinical Investigation

Volumn 43, Issue 3, 2013, Pages 248-255

  Ekström, Lena ^a   Cevenini, Luca ^b   Michelini, Elisa ^b   Schulze, Jenny ^a   Thörngren, John Olof ^c   Belanger, Alain ^d   Guillemette, Chantal ^d   Garle, Mats ^a,c   Roda, Aldo ^b   Rane, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Université Laval   (Canada)

Author keywords

Androgen receptor activity; Doping; Testosterone; UGT2B17

Indexed keywords

5BETA ANDROSTANE 3ALPHA,17BETA DIOL; 5BETA ANDROSTANOLONE; ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; DIHYDROTACHYSTEROL; ETIOCHOLANOLONE; GLUCURONOSYLTRANSFERASE 2B7; TESTOSTERONE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE DELETION; GENOTYPE; GLUCURONIDATION; HORMONE ACTION; HUMAN; MALE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; URINALYSIS; URINE LEVEL;

ADOLESCENT; ADULT; ANDROGENS; DIHYDROTESTOSTERONE; DOPING IN SPORTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE DELETION; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; SUBSTANCE ABUSE DETECTION; TESTOSTERONE; YOUNG ADULT;

EID: 84873996101     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12037     Document Type: Article

References (18)

1. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006;91:687-93.
2. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, Rane A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008;93:2500-6.
3. Ekstrom L, Schulze JJ, Guillemette C, Belanger A, Rane A. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5′-diphospho-glucuronosyltransferase (UGT2B17) gene. Pharmacogenet Genomics 2011;21:325-32.
4. Zierau O, Lehmann S, Vollmer G, Schanzer W, Diel P. Detection of anabolic steroid abuse using a yeast transactivation system. Steroids 2008;73:1143-7.
5. Houtman CJ, Sterk SS, van de Heijning MP, Brouwer A, Stephany RW, van der Burg B et al. Detection of anabolic androgenic steroid abuse in doping control using mammalian reporter gene bioassays. Anal Chim Acta 2009;637:247-58.
6. Wolf S, Rataj F, Zierau O, Ostermann K, Diel P, Parr MK et al. A novel combined approach to detect androgenic activities with yeast based assays in Schizosaccharomyces pombe and Saccharomyces cerevisiae. Toxicol Lett 2010;199:410-5.
7. Wolf S, Diel P, Parr MK, Rataj F, Schanzer W, Vollmer G et al. Long-term detection of methyltestosterone (ab-) use by a yeast transactivation system. Arch Toxicol 2011;85:285-92.
8. Schulze JJ, Thorngren JO, Garle M, Ekstrom L, Rane A. Androgen sulfation in healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men. J Clin Endocrinol Metab 2011;96:3440-7.
9. Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007;103:178-88.
10. Hsing AW, Stanczyk FZ, Belanger A, Schroeder P, Chang L, Falk RT et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007;16:1004-8.
11. Roda A, Roda B, Cevenini L, Michelini E, Mezzanotte L, Reschiglian P et al. Analytical strategies for improving the robustness and reproducibility of bioluminescent microbial bioreporters. Anal Bioanal Chem 2011;401:201-11.
12. Michelini E, Cevenini L, Mezzanotte L, Leskinen P, Virta M, Karp M et al. A sensitive recombinant cell-based bioluminescent assay for detection of androgen-like compounds. Nat Protoc 2008;3:1895-902.
13. Schulze JJ, Lundmark J, Garle M, Ekstrom L, Sottas PE, Rane A. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids 2009;74:365-8.
14. Rijk JC, Bovee TF, Wang S, Van Poucke C, Van Peteghem C, Nielen MW. Detection of anabolic steroids in dietary supplements: the added value of an androgen yeast bioassay in parallel with a liquid chromatography-tandem mass spectrometry screening method. Anal Chim Acta 2009;637:305-14.
15. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. J Steroid Biochem Mol Biol 1993;44:179-89.
16. Deshmukh N, Petroczi A, Barker J, Szekely AD, Hussain I, Naughton DP. Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids. Subst Abuse Treat Prev Policy 2010;5:7.
17. Carlstrom K, Palonek E, Garle M, Oftebro H, Stanghelle J, Bjorkhem I. Detection of testosterone administration by increased ratio between serum concentrations of testosterone and 17 alpha-hydroxyprogesterone. Clin Chem 1992;38:1779-84.
18. Roda A, Cevenini L, Michelini E, Branchini BR. A portable bioluminescence engineered cell-based biosensor for on-site applications. Biosens Bioelectron 2011;26:3647-53.